PRESS MAIL NO.: EL615431388US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of:

LESTER, et al.

Art Unit: 1761

Appl. No.: 10/762,098

Filed: January 20, 2004

Confirmation No.: 4555

For:

SAVORY GLUTEN-FREE FOODS

Atty. Docket: 05533.0002.NPUS00

Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

Appl. No.: 10/792,098

herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
 - a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - □ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - □ c. Before the mailing date of a first Office Action on the merits;
 - □ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- □ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a foreign

 patent office in a counterpart foreign application not more than three

 months prior to the filing of this Information Disclosure Statement. 37

 C.F.R. § 1.97(e)(1), or
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or

Applicant(s): LESTER, et al. Appl. No.: 10/792,098

	□ c.	Attached is our Check No in the amount of \$ in payment of the
		fee under 37 C.F.R. § 1.17(p).
□ 3.	This I	nformation Disclosure Statement is being filed more than three months after the
		U.S. filing date and after the mailing date of a Final Rejection or Notice of
		Allowance, but on or before payment of the Issue Fee. Attached is our Check No.
		in the amount of \$ in payment of the fee under 37 C.F.R.
		§ 1.17(i), and
	□ a.	I hereby state that each item of information contained in this Information
		Disclosure Statement was first cited in any communication from a foreign
		patent office in a counterpart foreign application not more than three
		months prior to the filing of this Information Disclosure Statement. 37
		C.F.R. § 1.97(e)(1), or
	□ b.	I hereby state that no item of information in this Information Disclosure Statement
		was cited in a communication from a foreign patent office in a counterpart
		foreign application, and, to my knowledge after making reasonable
		inquiry, no item of information contained in this Information Disclosure
		Statement was known to any individual designated in 37 C.F.R. § 1.56(c)
		more than three months prior to the filing of this Information Disclosure
		Statement. 37 C.F.R. § 1.97(e)(2).
□ 4.	Releva	ance of the non-English language document(s) is discussed in the present
		specification.
□ 5.	The d	ocument(s) was/were cited in a corresponding foreign application. An English
		language version of the foreign search report is attached for the Examiner's
		information.
□ 6.	A con	cise explanation of the relevance of the non-English language document(s) appears
		below:
7 .	The I	Examiner's attention is directed to co-pending U.S. Patent Application No.
		, filed, which is directed to related technical subject matter.
		The identification of this U.S. Patent Application is not to be construed as a
		waiver of secrecy as to that application now or upon issuance of the present

Applicant(s): LESTER, et al.

Appl. No.: 10/792,098

application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

- 4 -

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05533.0002.NPUS00.

Respectfully submitted,

Date: 4 3 64

Albert P. Halluin (Reg. No. 25,227) Katharine L. Altemus (Reg. No.51,396)

HOWREY SIMON ARNOLD & WHITE, LLP Box No. 34 301 Ravenswood Avenue Menlo Park, CA 94025 650/463-8109



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY, DOCKET NO.	APPLICATION NO.					
05533.0002.NPUS00	Not yet					
	assigned					
APPLICANT						
LESTER, et al.						
FILING DATE	GROUP					
January 20, 2004	1642					

			U.S. PATE	NT DOCUMENTS						
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		FILING DATE		
	1.	5,536,522	07/16/1996	Seeds, et al.						
	2.	6,013,294	01/11/2000	Bunke, et al.						
	3.	6,056,984	05/02/2000	Ekanayake et al.						
	4.	6,613,366	09/02/2003	Fitzpatrick						
	5.	2002/0165125 A1	11/07/2002	Merrill et al.				<u></u>		
	6.	2003/0203096	10/30/2003	Hamm et al.						
		f	OREIGN PA	TENT DOCUMENTS	·					
*EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSL	ATION	
INITIAL								YES	NO	
	7.	WO 00/30673	06/02/2000	PCT				х		
	8.	WO 01/94629	12/13/2001	РСТ				x		
		(Including		REFERENCES Date, Pertinent Pages, I	Etc.)					
	9. Abdulkarim, A.S. et al., "The diagnosis of celiac disease", Ailment. Pharmacol. Ther., 17(8):9 995 (2003)								7-	
	10.	Chin, R.L. et al., Celiac Neuropathy, Neurology, 30(10):1581-1585 (2003)								
	11.	Greer, R. "Easy Gluten-Free Cooking" Thorsons, London: 42-43 (2001)								
	12.	Michael, M., "Recognizing and managing celiac disease in primary care", <i>J. Am. Acad. Nurse Pract.</i> , 15(3):108-114 (2003)								
	13.	Tierney Jr., L.M. et al., Current Medical Diagnosis & Treatment 585-587 (2003)								
	14.	http://www.glutenfreemall.com								
	15.	http://www.panix.com/~pateodiet/list/soups/htm								
	16.							•		
	17.							•		
	18.				-			_		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.